A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Linsitinib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 27 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Nov 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 09 Nov 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2017.